Open AccessSARS-CoV-2 Antibody Longitudinal Profile of Immune Globulin Preparations
Author(s) -
Hyun Jung Park,
Karl C. Alcover,
Qing Wang,
Satyen M. Gada
Publication year - 2022
Publication title -
military medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.442
H-Index - 67
eISSN - 1930-613X
pISSN - 0026-4075
DOI - 10.1093/milmed/usac192
Subject(s) - antibody , medicine , vaccination , population , immunology , pandemic , herd immunity , immunity , antibody titer , immune system , virology , covid-19 , titer , disease , infectious disease (medical specialty) , environmental health
Intravenous immunoglobulin (IVIG) preparations, used for the treatment of antibody deficiencies, provide a glimpse of the general population's antibody profile as each preparation is generated from a pool of thousands of donors. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease 2019 (Covid-19) pandemic, and a vaccine for the prevention of Covid-19 was authorized for emergency use in December 2020. We completed a longitudinal analysis of SARS-CoV-2 antibody levels in commercial IVIG preparations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom